Fig. 3.

Successful use of epidermal growth factor receptor (EGFR) inhibitor osimertinib in a patient with advanced untreated EGFR mutated non-small cell lung cancer. Patient is a 60-yearold female who presented with thoracic pain, found to have a midthoracic pathologic compression fracture. Per discussion with medical oncology team, the consensus was for systemic treatment after a percutaneous spine fusion. Sagittal and axial magnetic resonance imaging cervical and thoracic spine prior to the initiation of treatment (A, B) and 4 months after treatment with osimertinib (C, D) showing resolution of the lesion.